<DOC>
	<DOCNO>NCT00804115</DOCNO>
	<brief_summary>Purpose : To determine efficacy treatment latanoprost combination pilocarpine versus timolol timolol/dorzolamide fix combination ( Timoptic Cosopt ) eye XFS elevate intraocular pressure ( IOP ) . Methods : This randomize , open-label study test hypothesis improve pressure-dependent pressure-independent aqueous outflow minimize iridolenticular friction interfere progression XFS , allow improvement trabecular function , effective time simply reduce aqueous formation . Randomization perform across center , per patient rather per eye avoid crossover effect cause aqueous suppressant . Group I treat latanoprost pilocarpine , evening , Group II Timolol Cosopt b.i.d . Only one eye per patient randomize . Patients follow 2 year assessment IOP , visual field progression , tonographic outflow coefficient trabecular pigmentation 6:00 12:00 position .</brief_summary>
	<brief_title>The International Collaborative Exfoliation Syndrome Treatment Study</brief_title>
	<detailed_description>Purpose : To compare effect treatment latanoprost plus pilocarpine v timolol fix combination timolol/dorzolamide ( T/D ) eye exfoliation syndrome ( XFS ) elevate IOP . Methods : A randomized , prospective , international , 12-center , two-year , open-label clinical trial conduct . XFS patient age 50-80 year untreated IOP ≥22 mmHg open angle without mild moderate glaucomatous damage include . One eligible eye per patient randomly assign latanoprost pilocarpine qhs increase aqueous outflow inhibit pupillary movement ( group I ) , decrease aqueous production timolol T/D bid need IOP control ( group II ) . IOP , tonographic outflow facility , trabecular pigmentation measure every 6 month . Results : 277 ( 146 male ) patient ( mean age 69.1±6.8 yr , range 50-80 yr ) ` enrol October 2000 July 2003 . XFS unilateral 118 ( 42.6 % ) bilateral 159 ( 57.4 % ) patient . Baseline TM pigmentation 6:00 angle significantly associate IOP ( p=0.01 ) . IOP reduction 1.3 mmHg great Group I ( n=145 ) Group II ( n=132 ) ( p=0.0003 ) . Mean increase outflow facility Group I 0.005 µl/mmHg/min v 0 μl/mmHg/min Group II ( p &lt; 0.001 ) . TM pigmentation 6:00 position 24 month decrease baseline frequently Group I Group II [ 34 ( 26 % ) v 20 ( 16 % ) ] increase baseline frequently Group II Group I [ 31 ( 25 % ) v 24 ( 18 % ) ] . Conclusions : Subjects Group I low IOP , improve outflow facility decrease TM pigmentation . Initial therapy increase aqueous outflow interfere dispersion exfoliation material iris pigment inhibit pupillary movement preferable reduce aqueous secretion , may deleterious primary treatment disorder .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Exfoliation Syndrome</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>1 . Exfoliation syndrome one eye . Exfoliation material must present anterior lens surface diagnosis . 2 . Untreated IOP great equal 22 mmHg one eye without mild moderate glaucomatous damage , judgment investigator , safely wash current medical therapy . 3 . Age 5080 year 4 . Open angle gonioscopy 1 . Age 80 year 2 . Best correct visual acuity le 20/30 3 . Untreated IOP great 35 mmHg 4 . Currently take systemic betablockers 5 . Glaucomatous damage sufficiently severe prevent washout opinion examiner visual field defect within 10 degree fixation 6 . Glaucoma exfoliation syndrome 7 . Absence exfoliation material lens surface eye treat 8 . Known allergy sensitivity study medication 9 . Ocular pathology may interfere ability obtain tonography , visual field , accurate IOP reading 10 . Angleclosure glaucoma 11 . Diabetic retinopathy 12 . Previous intraocular laser surgery . 13 . Unwilling unable give consent 14 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Exfoliation Syndrome</keyword>
	<keyword>Latanoprost</keyword>
	<keyword>Timolol</keyword>
	<keyword>Pilocarpine</keyword>
</DOC>